EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Klinische Studie (Phase III)

Prior antibiotics, proton pump inhibitors, and probiotics in patients with extensive stage small cell lung cancer treated with immune checkpoint blockade: A post‐hoc analysis of the phase I/ III IMpower 133 trial

Kazuki Takada, Shinkichi Takamori, Mototsugu Shimokawa, David J Pinato iD, Alessio Cortellini iD

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35249 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Kazuki Takada und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Saiseikai Fukuoka General Hospital, Fukuoka, Japan. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Immune Checkpoint Inhibitors, Lung Neoplasms, Probiotics. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The potential impact of concomitant medications such as systemic antibiotics, proton pump inhibitors (PPIs), and probiotics in patients with extensive‐stage small cell lung cancer (ES‐SCLC) receiving first‐line chemo‐immunotherapy combinations remains unclear. We ran a post hoc analysis of the IMpower133 phase I/III trial, which randomized patients with ES‐SCLC to receive carboplatin/etoposide with either atezolizumab or placebo for 4 cycles, followed by maintenance therapy. We included any systemic antibiotic/probiotic exposure within 42 days prior to treatment initiation and any PPIs treatment within 30 days prior to treatment initiation. We explored the potential prognostic impact of antibiotics, PPIs and probiotics across the atezolizumab/chemotherapy and placebo/chemotherapy arms including the multivariable interaction term between the treatment modality and antibiotics/PPIs/probiotics. The analysis included 198 patients in the atezolizumab/chemotherapy arm and 195 in the placebo/chemotherapy arm. Baseline clinic‐pathologic features were well balanced between the two cohorts, with 17 (8.6%) and 14 (7.2%) patients on antibiotics, 43 (21.7%) and 55 (28.2%) on PPIs, and 3 (1.5%) and 5 (2.6%) on probiotics among the atezolizumab/chemotherapy and placebo/chemotherapy cohorts, respectively. Exposure to antibiotics, PPIs, or probiotics was not associated with overall survival or progression free survival in either cohort. Furthermore, interaction terms between these medications and treatment modalities were not statistically significant. Baseline use of antibiotics, PPIs or probiotics did not influence clinical outcomes in patients with ES‐SCLC treated with first‐line atezolizumab/placebo plus chemotherapy, suggesting that they may not have a notable impact on clinical outcomes and could be considered for use in this patient population when necessary.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsImmune Checkpoint InhibitorsLung NeoplasmsProbioticsProton Pump InhibitorsSmall Cell Lung CarcinomaAdultAgedFemaleHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarboplatinEtoposideNeoplasm Staging

Stichwörter der Autor:innen

antibioticsatezolizumabprobioticsproton pump inhibitorssmall cell lung cancer

Substanzen

Anti-Bacterial AgentsAntibodies, Monoclonal, HumanizedatezolizumabCarboplatinEtoposideImmune Checkpoint InhibitorsProton Pump Inhibitors

Autor:innen und Institutionen

  • Department of Surgery, Saiseikai Fukuoka General Hospital, Fukuoka, Japan.
  • Department of Thoracic and Breast Surgery, Oita University Faculty of Medicine, Oita, Japan.
  • Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
  • Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.
  • Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
  • Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.

ORCID-Profile: David J Pinato, Alessio Cortellini

Zitieren

APA

Takada, K., Takamori, S., Shimokawa, M., Pinato, D. J., & Cortellini, A. (2025). Prior antibiotics, proton pump inhibitors, and probiotics in patients with extensive stage small cell lung cancer treated with immune checkpoint blockade: A post‐hoc analysis of the phase I/ III IMpower 133 trial. International Journal of Cancer. https://doi.org/10.1002/ijc.35249

Vancouver

Takada K, Takamori S, Shimokawa M, Pinato DJ, Cortellini A. Prior antibiotics, proton pump inhibitors, and probiotics in patients with extensive stage small cell lung cancer treated with immune checkpoint blockade: A post‐hoc analysis of the phase I/ III IMpower 133 trial. International Journal of Cancer. 2025. doi:10.1002/ijc.35249

BibTeX
@article{Takada2025,
  author = {Takada, Kazuki and Takamori, Shinkichi and Shimokawa, Mototsugu and Pinato, David J and Cortellini, Alessio},
  title = {Prior antibiotics, proton pump inhibitors, and probiotics in patients with extensive stage small cell lung cancer treated with immune checkpoint blockade: A post‐hoc analysis of the phase I/ III IMpower 133 trial},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35249}
}
Kostenlos starten →